Lessons learned from BATTLE-2 in the war on cancer: the use of Bayesian method in clinical trial design.

about

Ethical considerations of neuro-oncology trial design in the era of precision medicine.MEK inhibitors under development for treatment of non-small-cell lung cancer.Tumor molecular profiling of NSCLC patients using next generation sequencing.Precision oncology: neither a silver bullet nor a dream.

P2860

Q39337327-A9532A52-EDE7-4667-8065-0245CA1DF338 Q47318847-623DC086-5809-44B5-9FA2-81F32BD40116 Q47710730-26A38483-8078-4CD2-A69D-2F74C651AFCD Q47737073-36AC8D30-A06C-43C1-B07F-D254F8011684

P2860

Lessons learned from BATTLE-2 in the war on cancer: the use of Bayesian method in clinical trial design.

Item

http://www.wikidata.org/entity/Q42332672

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

Lessons learned from BATTLE-2 ...... thod in clinical trial design.

@en

Lessons learned from BATTLE-2 ...... thod in clinical trial design.

@nl

type

Item

label

Lessons learned from BATTLE-2 ...... thod in clinical trial design.

@en

Lessons learned from BATTLE-2 ...... thod in clinical trial design.

@nl

prefLabel

Lessons learned from BATTLE-2 ...... thod in clinical trial design.

@en

Lessons learned from BATTLE-2 ...... thod in clinical trial design.

@nl

P1476

Lessons learned from BATTLE-2 ...... thod in clinical trial design.

@en

P2093

Chul Kim

http://www.w3.org/2001/XMLSchema#string

P2860

K-Ras protein as a drug target

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy.

Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study.

Ceritinib in ALK-rearranged non-small-cell lung cancer.

Crizotinib in ROS1-rearranged non-small-cell lung cancer.

The BATTLE trial: personalizing therapy for lung cancer.

Outcome--adaptive randomization: is it useful?

EGFR mutation is a better predictor of response to tyrosine kinase inhibitors in non-small cell lung carcinoma than FISH, CISH, and immunohistochemistry

Molecular profiling and targeted therapy for advanced thoracic malignancies: a biomarker-derived, multiarm, multihistology phase II basket trial

KRAS mutations affect prognosis of non-small-cell lung cancer patients treated with first-line platinum containing chemotherapy

P304

466

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

editorial

P356

10.21037/ATM.2016.11.48

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Giuseppe Giaccone

P577

2016-12-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28090522

http://www.w3.org/2001/XMLSchema#string

P932

5220042

http://www.w3.org/2001/XMLSchema#string

Lessons learned from BATTLE-2 in the war on cancer: the use of Bayesian method in clinical trial design.

about

P2860

P2860

Lessons learned from BATTLE-2 in the war on cancer: the use of Bayesian method in clinical trial design.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P932